Helmholtz Munich and Parse Biosciences have initiated a strategic collaboration to create the world's largest lung disease perturbation atlas by profiling cellular responses to 900 pharmacological agents using human lung tissue slices. Powered by Parse’s high-throughput single-cell RNA sequencing platform, this project aims to reveal drug effects at single-cell resolution, accelerating the identification of therapeutic targets for chronic lung diseases. AI models developed from this dataset could drive precision regenerative therapies.